TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05049070

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mobile medical application to self administer a subjective refraction test
Description: GoEyes is a software as a medical device and mobile medical application, which is downloaded to a smartphone and is a self-administered subjective refraction test that measures the refractive error of the user's eyes in the home environment without any contact or help from health care professionals

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard of care refraction test
Description: Standard of care subjective manifest refraction test performed by a healthcare professional
Study: NCT05947201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil
Description: If the addition of Cadonilimab to neoadjuvant chemotherapy further improve the efficiency for locally advanced esophageal squamous cell carcinoma
Study: NCT06069479

Intervention type: PROCEDURE
Intervention: craniofacial surgery
Description: Surgical treatment, either stripcraniectomy or fronto-orbital advancement
Study: NCT05602987

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enema
Description: receiving enema at the night before anal surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no enema
Description: no enema before anal surgery
Study: NCT05188092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasound guided deresuscitation
Description: With every new LUS examination, the following scenarios, with distinct recommendations, are possible:~1. LUS observations suggest massive pulmonary fluid overload, with the recommendation to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance of at least -1500 ml in the next 24 hours;~2. LUS suggests some pulmonary edema and/or significant pleural effusion. These LUS observations suggest little pulmonary fluid overload, with the suggestion to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance at least -500 ml in the next 24 hours;~3. LUS suggests absence of pulmonary edema and no pleural effusion. These LUS observations suggest no fluid overload, with the suggestion to target a neutral fluid balance in the next 24 hours.
Study: NCT05174039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat 100Mg Oral Capsule
Description: Subjects will initiate miglustat at Week 1 and dosing will be escalated until 600mg/d. If a subject has not reached the maximum dose (600 mg/d) by Week 8, the Week 8 dose will be subject's MTD.
Study: NCT04964128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed™ 780G insulin pump with Klue Health app utilizing meal gesture micro insulin dosing (meal gesture dosing)
Description: The AHCL system with Meal Gesture Dosing evaluated in this study includes a commercial/CE-Marked insulin pump with investigational software, and the Klue Health mobile app with investigational software (installed on Apple Watch) for meal gesture detection and micro dosing.
Study: NCT05628909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPV with SO tamponade
Description: Patients randomized into silicone oil group were received pars plana vitrectomy surgery with silicone oil tamponade and without internal limiting membrane peeling. And silicone oil tamponade was removed at least 12 months after the primary surgery with completely resolved of foveoschisis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV with fovea-sparing ILMP and gas tamponade
Description: Patients randomized into gas group 1 were received pars plana vitrectomy surgery with fovea-sparing internal limiting membrane peeling and gas tamponade.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV with gas tamponade
Description: Patients randomized into gas group 2 were received pars plana vitrectomy surgery without internal limiting membrane peeling and gas tamponade.
Study: NCT05174169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPOX 6 month
Description: Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles
Study: NCT04889872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA
Description: Patients will be implanted with a SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA heart valve
Study: NCT05302648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Derived anti-BCMA CAR-T Injection
Description: Autologous genetically modified anti-BCMA CAR transduced T cells
Study: NCT06111781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Relugolix 120 MG [Orgovyx]
Description: ORGOVYX will be initiated with a loading dose of 360 mg on the first day and continue treatment with a 120 mg dose taken orally once daily at approximately the same time each day. Total length of treatment will be 30 days.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT standard of care radiotherapy treatment
Description: SBRT is a standard-of-care radiotherapy treatment for intermediate-risk prostate cancer.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT standard of care radiotherapy treatment
Description: SBRT is a standard-of-care radiotherapy treatment for intermediate-risk prostate cancer.
Study: NCT05458323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free near and Distance Vision glasses
Description: Intervention Description: All participants randomised to the intervention group will be provided with free near and/or distance spectacles based on the results of refraction.Glasses will be provided at the time of enrolment in the study.
Study: NCT05864911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Gastric Bypass Stent System
Description: The Gastric Bypass Stent System is a newly designed endoscopic duodenal-jejunal bypass liner for the treatment of obesity by Hangzhou Tangji Medical Technology Co., Ltd.. It consists of three main parts: a 60-cm polyethylene sleeve fixed into the duodenal bulb by anchors with barbs, a delivery system and a retrieval system. Compared to the Endobarrier, it has several technical adjustments. First, it improved sleeve materials to provide better barrier properties and reduce the breeding of bacteria resulting in hepatic abscess. Second, the barbs on the anchoring system have been modified to reduce duodenal injury. Third, the delivery and retrieval system have been optimized to eliminate the need of fluoroscopic guidance during implantation and explantation.
Study: NCT05188209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG003
Description: Administered intravenously
Study: NCT05766930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The novel electrolyzed water spray
Description: Study staff will use the novel electrolyzed water spray device and spray for approximately 2-4 minutes on the participant's diseased area until half a bottle (20-40ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The relief genital itching evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
Study: NCT05441527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MI Paste, then, Biotene Dry Mouth Gel
Description: 1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotene Dry Mouth Gel, then, MI Paste
Description: 1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
Study: NCT05190198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation
Description: * Weight shifting in each direction (anteriorly, posteriorly, and lateral side) combined with side-to-side head movements (5 times for each direction).~* One-legged stance with slight knee flexion of another leg for 15 seconds (5 times for each leg).~* One-legged stance with increasing knee flexion of the other leg for 15 seconds (5 times for each leg).~* Standing on a balance pad with shifting weight (anteriorly, posteriorly, and lateral side) 10 times in each direction.~* In standing position, moving the weight left and right maximally.~* In standing position, moving the weight forward and backward maximally.~* In standing position, moving both heels of feet up and down.~* In standing position, bending and stretching both knees by squatting as much as possible.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: (Dorsiflexion, planter flexion, eversion and inversion) 10 repetitions for each movement.~(A) Sit to stand (5 times). (B) Standing with shifting Weight anteriorly, posteriorly, and sideway (5 times for each direction). (C) Functional reach sideway and anterior for touching targets set by the therapist (5 times for each direction). (D) Standing on heels for 20 seconds (5 times). (E) Standing on toes for 20 seconds (5 times).~(A) Spot marching (2 min). (B) Walking over the heels, toes, lateral border of feet with the preferred speed (6 min). (C) Tandem walking in a straight line (2 min).
Study: NCT04928677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codrituzumab
Description: For Phase A (Dose Escalation), the starting dose (dose level 1) will be 10 mg/kg with 1 planned dose escalation to 20 mg/kg (dose level 2) if dose level 1 is determined to be safe and tolerable. Once a RP2D/MTD is identified in Phase A, then Phase B (hepatoblastoma expansion cohort) will open and allow for enrollment of up to 10 additional patients.For both phases, patients will receive codrituzumab IV once per week for a period of 21 days per cycle. Patients will be eligible for up to 25 cycles.
Study: NCT05700435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management and Resilience Training
Description: The Stress Management and Resilience Training (SMART) program focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) or in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks. The modalities VTC and in-person are the two intervention conditions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management and Resilience Training
Description: The Stress Management and Resilience Training (SMART) program focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) or in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks. The modalities VTC and in-person are the two intervention conditions.
Study: NCT05568784

Intervention type: OTHER
Intervention: Straight Leg Raise exercise
Description: Patient lying supine will lift leg to the height of the contralateral knee flexed to 90 degrees with the ankle positioned and tested in all three positions (dorsiflexion, neutral, and plantarflexion)

Intervention type: OTHER
Intervention: Straight Leg Raise exercise
Description: Patient lying supine will lift leg to the height of the contralateral knee flexed to 90 degrees with the ankle positioned and tested in all three positions (dorsiflexion, neutral, and plantarflexion)
Study: NCT06275282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intramuscular electrodes
Description: Participants will have regenerative peripheral nerve interfaces (RPNIs) created on nerves in their residual thighs. During either the same surgery or a separate surgery, small electrodes will be implanted into these RPNIs.
Study: NCT06341738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video education about HPV and HPV vaccine
Description: video animation in 8 minutes to promote about HPV and HPV vaccine. the video is played in front of class using LCD projector.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic reminder messages
Description: Reseachers send reminder messages twice per vaccination event (e.g., 7 days and 1 day before vaccination event), with a total of four times sending reminder messages using the app on the smartphone.
Study: NCT06264206

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Killer-cell immunoglobulin-like receptors (KIRs) testing
Description: patients were tested for KIRs, and based on the divided in the 2 arms. Patient from ARM KIR AA received immunomuodulatorc treatment.
Study: NCT05752110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0,5mg/kg single dose Ketamine (0.05ml/kg) intravenously administered

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.09% Saline (0.05ml/kg) intravenously administered
Study: NCT06456333

Intervention type: DEVICE
Intervention: High-density surface electromyography
Description: Electromyographic signals were acquired from the paravertebral muscles in apical vertebral in patients with AIS using SAGA High Density Myoelectrics (TMSi International, New Zealand)

Intervention type: DEVICE
Intervention: High-density surface electromyography
Description: Electromyographic signals were acquired from the paravertebral muscles in apical vertebral in patients with AIS using SAGA High Density Myoelectrics (TMSi International, New Zealand)
Study: NCT06341738

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Information Service
Description: this usual information (e.g., the HPV vaccination event) was delivered face-to-face by staff in front of class
Study: NCT06418503

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Balance Training
Description: Participants will complete 16 sessions of balance training (30 min. each) over one month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMG-Biofeedback Training
Description: Participants will complete 16 sessions of EMG-biofeedback balance training (30 min. each) over one month.
Study: NCT05112380

Intervention type: OTHER
Intervention: Performing Xco endurance test
Description: The subjects will perform the test two times, with 7-10 days between the two sessions

Intervention type: OTHER
Intervention: Performing Xco endurance test
Description: The subjects will perform the test two times, with 7-10 days between the two sessions
Study: NCT05566210

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture
Study: NCT04662801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL)
Description: All participants will receive twelve weeks of BWL treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL)
Description: All participants will receive twelve weeks of BWL treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Responder: BWL continued
Description: Participants categorized as experiencing early weight loss at the end of the first month of treatment will continue with BWL for the remainder of treatment.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Early Non-responder: BWL continued with medication added
Description: Participants categorized as not experiencing early weight loss at the end of the first month of treatment will continue BWL plus a weight loss medication (Naltrexone Bupropion) for the remainder of treatment.
Study: NCT06316531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M07D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT05263895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-07321332/ritonavir
Description: PF-07321332 ritonavir will be administered as single dose orally
Study: NCT04978818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaxelis
Description: Eligible infants will be block randomized to one of two study arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PedvaxHIB
Description: Eligible infants will be block randomized to one of two study arms.
Study: NCT05964543

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Q-1802 Injection,Oxaliplatin Injection,Capecitabine
Description: Q-1802：A dose Q-1802 will be administered intravenously Q2W. XELOX（oxaliplatin，capecitabin）: 21 days as a cycle Oxaliplatin will be administered 130mg/m2 as a 2-hour IV infusion,administer once on the first day, with 21 days as a cycle Capecitabine will be administered 1000mg/m2 orally twice daily (D1-D14),21ds is one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q-1802 Injection,Oxaliplatin Injection,Capecitabine
Description: Q-1802：A dose Q-1802 will be administered intravenously Q2W. XELOX（oxaliplatin，capecitabin）: 21 days as a cycle Oxaliplatin will be administered 130mg/m2 as a 2-hour IV infusion,administer once on the first day, with 21 days as a cycle Capecitabine will be administered 1000mg/m2 orally twice daily (D1-D14),21ds is one cycle.
Study: NCT05263895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir
Description: PF-07321332 ritonavir will be administered as single oral dose orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir
Description: PF-07321332 ritonavir will be administered as single oral dose orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir
Description: PF-07321332 ritonavir will be administered as single oral dose orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332
Description: PF-07321332 will be administered as single oral dose orally.
Study: NCT05904457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Patients will receive bevacizumab 10 mg/kg IV over 30-90 minutes every 2 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Patients will receive elrotinib 150 mg orally once a day continuously until disease progression or unacceptable toxicity.
Study: NCT05403879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fixation of greater tuberosity fractures
Description: deltopectoral approach for shoulder, then open reduction and fixation of displaced greater tuberosity fractures using hooked Kirshner wires
Study: NCT05133687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).
Study: NCT06429501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine/Epinephrine
Description: injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: injection
Study: NCT04075487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-module for patient education and planning
Description: Our goal is a mobile web-based application (App) that provides immediate feedback to Veterans seeking to develop their own pain self-management plan
Study: NCT05797493

Intervention type: DRUG
Intervention: Atezolizumab
Description: Upfront chemo-immunotherapy
Study: NCT04840914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3461767
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT05814406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JW0201
Description: JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
Study: NCT06092866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital triage
Description: A registered nurse assesses the symptoms reported by the patient on the online platform and gives appropriate advice for further care using chat.
Study: NCT06180707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin gel
Description: 10% pregabalin gel (carbopol-based gel to which the drug has been added) for topical application to teeth before bleaching with hydrogen peroxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gel with 5% potassium nitrate and 2% sodium fluoride
Description: gel of 5% potassium nitrate and 2% sodium fluoride for topical application to teeth before bleaching with hydrogen peroxide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: placebo gel (carbopol-based gel 1%) for topical application to teeth before bleaching with hydrogen peroxide
Study: NCT04794023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corneal Ablation
Description: Corneal ablation for the treatment of myopia with/without astigmatism following flap creation using femtosecond laser.
Study: NCT05367323

Intervention type: DEVICE
Intervention: Pressure algometry (Baseline 2.2-Pound Dolorimeter) and Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)
Description: Both instruments are used for the assessment of the L4-5 interspinous space pain pressure threshold and the biomechanical-viscoelastic properties of L4-5 supraspinous ligament respectively

Intervention type: DEVICE
Intervention: Pressure algometry (Baseline 2.2-Pound Dolorimeter) and Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)
Description: Both instruments are used for the assessment of the L4-5 interspinous space pain pressure threshold and the biomechanical-viscoelastic properties of L4-5 supraspinous ligament respectively